Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, Turitto G, Scandurra G, Petrella MC, Forestieri V, Rizzetto M, Mammoliti S, Artioli G, Cioffi R, Borsotti L, Bellero M, Rognone C, Carbone V, Ferrandina G, Mantiero M, Azzolina C, Geninatti E, Pignata S, Valabrega G.
Tuninetti V, et al. Among authors: rizzetto m.
Eur J Cancer. 2024 May;203:114039. doi: 10.1016/j.ejca.2024.114039. Epub 2024 Mar 30.
Eur J Cancer. 2024.
PMID: 38598922